MUC16 and cancer: The capacity of nanobody S1 to target MSLN+ cells was evaluated by flow cytometry on a panel of cancer cell lines from different cancers, expressing various levels of MSLN and of its ligand MUC16 (Figure 1A; Supplementary Figures 1A, B).